Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Operating Margin of 49.02% for Q1 2026, up 20.96% on a QoQ basis from 40.52% in Q4 2025, and up 421.0% year-over-year from 9.41% in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Operating Margin history runs 9 years deep, the most recent figure standing at 49.02% for Q1 2026.
- Quarterly Operating Margin rose 421.0% year-over-year to 49.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.83% (up 156.0% YoY) and the FY2025 annual result came in at 43.77%, up 409.0% from the prior year.
- Operating Margin was 49.02% for Q1 2026 at Catalyst Pharmaceuticals, up from 40.52% in the prior quarter.
- Across five years, Operating Margin topped out at 53.79% in Q2 2022 and bottomed at 36.21% in Q3 2023.
- A 5-year average of 38.74% and a median of 44.21% in 2024 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2023 — Operating Margin plunged 8007 bps — and 2024, when it surged 7577 bps.
- Catalyst Pharmaceuticals' Operating Margin stood at 50.7% in 2022, then fell by 26 bps to 37.71% in 2023, then advanced by 18 bps to 44.31% in 2024, then decreased by 9 bps to 40.52% in 2025, then climbed by 21 bps to 49.02% in 2026.
- Business Quant data shows CPRX's Operating Margin at 49.02% in Q1 2026, 40.52% in Q4 2025, and 44.66% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 49.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.02% |
| Dec 31, 2025 | 40.52% |
| Sep 30, 2025 | 44.66% |
| Jun 30, 2025 | 45.24% |
| Mar 31, 2025 | 44.81% |
| Dec 31, 2024 | 44.31% |
| Sep 30, 2024 | 39.56% |
| Jun 30, 2024 | 44.21% |
| Mar 31, 2024 | 27.54% |
| Dec 31, 2023 | 37.71% |
| Sep 30, 2023 | -36.21% |
| Jun 30, 2023 | 46.90% |
| Mar 31, 2023 | 41.71% |
| Dec 31, 2022 | 50.70% |
| Sep 30, 2022 | 43.85% |
| Jun 30, 2022 | 53.79% |
| Mar 31, 2022 | 40.30% |
| Dec 31, 2021 | 33.26% |
| Sep 30, 2021 | 38.95% |
| Jun 30, 2021 | 43.55% |